CompletedPhase 4ACTRN12612000010897

Antibiotics for treatment of bronchiectasis exacerbations in children - The Bronchiectasis Exacerbation Study (Study 2).

A randomised, double blind trial of Azithromycin versus Amoxycillin-Clavulate to treat mild to moderate respiratory exacerbations in children with non-Cystic Fibrosis bronchiectasis, Study Two.

Sponsor

Qld Children's Medical Research Institute

Enrollment

170 participants

Start Date

Oct 1, 2012

Study Type

Interventional

Conditions

Bronchiectasis

Summary

Our national study aims to improve the management of bronchiectasis in children, a lung condition that is common in Indigenous people worldwide, and also occurs in non-Indigenous people. This study aims to discover whether treating respiratory exacerbations with one of two different oral antibiotics is more effective at resolving the exacerbation. The results of this study will impact on national and international guidelines and substantially advance knowledge on exacerbations of childhood bronchiectasis.

Eligibility

Sex: Both males and femalesMax Age: 19 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares different antibiotic treatments for flare-ups of bronchiectasis (chronic lung damage with recurring infections) in children under 18. Participants must have confirmed bronchiectasis and at least 2 respiratory flare-ups in the past 18 months. Children with cystic fibrosis, liver problems, pseudomonas infection in the last 4 months, allergy to the study antibiotics, or currently being treated for cancer are excluded.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Arm 1: Daily oral Azithromycin 5mg/kg for 21 days Arm 2: Twice daily oral Amoxycillin-Clavulanic Acid 22.5mg/kg for 21 days These treatments are administered at the onset of respiratory exacerbati

Arm 1: Daily oral Azithromycin 5mg/kg for 21 days Arm 2: Twice daily oral Amoxycillin-Clavulanic Acid 22.5mg/kg for 21 days These treatments are administered at the onset of respiratory exacerbation after enrolment, and are administered only for one respiratory exacerbation.

Locations(1)

Auckland, New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12612000010897

Related Trials

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892494 locations

Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases

NCT069833661 location